Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study.~2. Female subjects must not be pregnant.~3. Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, or Mood Disorder~4. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months prior to screening.~5. Have moderate or severe TD~6. If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder, be on stable doses.~7. Be in general good health.~8. Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.~9. Have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids.~Exclusion Criteria~1. Have an active, clinically significant unstable medical condition within 1 month prior to screening.~2. Have a known history of substance dependence, substance (drug) or alcohol abuse.~3. Have a significant risk of suicidal or violent behavior.~4. Have a known history of neuroleptic malignant syndrome.~5. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.~6. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).~7. Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.~8. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.~9. Have an allergy, hypersensitivity, or intolerance to tetrabenazine.~10. Are currently pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dose Group 1 (Type: EXPERIMENTAL): Fixed dose of NBI-98854 administered once daily for 48 weeks
- Dose Group 2 (Type: EXPERIMENTAL): Fixed dose of NBI-98854 administered once daily up to 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).